Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.2752W HIGH $52.91
Volume
1.38 M
Value Traded
46.75 M
Short % Float
7.09%
-3.24%Week
-23.46%1 Month
-10.84%3 Month
+13.2%6 Month
+92.56%5 Year
+923.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.95 B
EPS (TTM)
-0.57
P/E Ratio
-
Ent. Value
1.83 B
Total Shares
53.78 M
Float Shares
57.23 M
Insiders
2.45%
Institutions
96.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AXGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Axogen, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Axogen, Inc.
13Total events
3Upcoming
4Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 5
▼Equity OfferingCorporate
Pricing of $208.7M public offering of 4,910,000 common shares at $42.50/share
▲AcquiredCorporate
Axogen enters definitive agreement to acquire BioCircuit Technologies for $200M cash
Past FDA Catalysts and PDUFA Decisions
How AXGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-03 | Avance® Nerve Graft | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$400M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 76%
Small Cap(rank 500 of 658)
Percentile Rank
Axogen, Inc. faces pipeline headwinds (27/100), with $615M risk-adjusted pipeline value, led by Processed Nerve Allograft in Peripheral Nerve Discontinuities (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Processed Nerve Allograft Monoclonal antibodyCompletedNCT01809002 | Peripheral Nerve Discontinuities | Phase 3 | COMPLETED | 220 | Aug 30, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every AXGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Axoguard Nerve Cap | symptomatic neuroma | 2024-01-18 | The REPOSE clinical trial demonstrated that the Axoguard Nerve Cap significantly reduced total pain compared to standard neurectomy, achieving statistical superiority with a p-value <0.05 at the 12-month follow-up.Read More | Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve CapRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TYNDALL JOSEPH A.Director | Sell | -3,500 10,650 held | $49.70 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AXGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.4 % | 46.72 M | 1.01 M |
AXGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AXGN ranks across every disease it competes in
Competitive Position is a premium feature
See how AXGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAXGN News
AXGN▼ -6.3%on this news
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Axogen, Inc. has completed its acquisition of BioCircuit Technologies, known for its NerveTape™, the first FDA-cleared sutureless device for peripheral nerve repair. This acquisition is expected to significantly enhance Axogen's revenue, contributing approximately $6 million in Q4 2026 and $34 million in 2027. The integration of NerveTape™ aligns with Axogen's goal of improving standards in nerve repair.
Read more →AXGN▼ -11.5%on this news
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Axogen, Inc. announced a public offering of 4,910,000 shares at $42.50 each, aiming to raise about $208.7 million. The funds will primarily support the acquisition of BioCircuit Technologies, with a closing date expected on September 11, 2026. The offering is contingent upon customary closing conditions.
Read more →AXGN▼ -11.5%on this newsshared move
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Axogen has entered into a definitive agreement to acquire BioCircuit Technologies for $200 million, enhancing its portfolio with NerveTape™, the first FDA-approved sutureless nerve repair device. This acquisition is anticipated to accelerate market adoption and improve revenue growth and EBITDA margins in the first year post-closing. The transaction is expected to close in Q4 2026, pending customary conditions.
Read more →AXGNAxogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen, Inc. will participate in the 24th Annual Morgan Stanley Global Healthcare Conference on September 15, 2026. The company is known for its innovative surgical solutions aimed at restoring peripheral nerve function. Management will be available for one-on-one investor meetings, highlighting their commitment to engaging with stakeholders.
Read more →AXGNTrace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
Trace Biosciences has secured a strategic investment from Axogen to advance its Nerve Trace imaging technology, which enhances nerve visibility during surgery. This funding will support ongoing Phase II and III clinical trials following the FDA clearance of their lead candidate, Nerve Trace Dx. The collaboration aims to improve surgical outcomes by allowing surgeons to visualize nerves in real time.
Read more →AXGNAxogen, Inc. Reports Second Quarter 2026 Financial Results
Axogen, Inc. reported a 23.1% increase in revenue for Q2 2026, totaling $69.7 million. Despite a net loss of $1.5 million, adjusted net income rose to $7.3 million. The company highlighted growth across various markets and the initiation of significant clinical studies aimed at nerve repair. Axogen anticipates full-year revenue growth of at least 24%.
Read more →AXGNAxogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Axogen, Inc. will report its financial results for the second quarter of 2026 on July 29, 2026. Following the release, management will host a conference call and webcast for the investment community. The company focuses on innovative solutions for peripheral nerve repair and aims to set a standard of care in this field.
Read more →AXGNAxogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Axogen, Inc. will participate in the 2026 Bank of America Global Healthcare Conference, with management scheduled to present on May 13, 2026. The event will be accessible via a live audio webcast on the company's website. Axogen is focused on innovative surgical solutions for peripheral nerve function restoration.
Read more →AXGN▲ +6.6%on this newsshared move
Axogen, Inc. Reports First Quarter 2026 Financial Results
Axogen, Inc. reported a strong financial performance for Q1 2026, with revenues reaching $61.5 million, a 26.6% increase from the previous year. The company also saw improvements in gross margin and adjusted net income. However, it faced a net loss of $19.6 million, highlighting ongoing challenges in profitability. The firm remains optimistic about its growth trajectory and strategic objectives for the year.
Read more →AXGNAxogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
Axogen, Inc. has announced it will release its financial results for the first quarter of 2026 on April 28, 2026. Following the release, the management will host a conference call and webcast for investors. The company focuses on developing technologies for peripheral nerve repair and aims to set a standard of care in this field.
Read more →AXGN▼ -8.1%on this news
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
Axogen, Inc. reported strong financial results for Q4 and full-year 2025, highlighting significant achievements including FDA approval for Avance®, the only implantable biologic for peripheral nerve treatment. The company anticipates at least 18% revenue growth for 2026, reflecting confidence in its strategic plan and market development strategies. Axogen aims to make peripheral nerve restoration a standard of care.
Read more →AXGNAxogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. has announced its participation in three upcoming investor conferences, including the Raymond James 47th Annual Institutional Investors Conference, the Leerink Global Healthcare Conference, and the Citizens Life Sciences Conference. These events will feature presentations and fireside chats, allowing management to engage with investors. Webcast links for the events are provided for live access and replays.
Read more →AXGNAxogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Axogen, Inc. has announced that it will release its financial results for the fourth quarter and full year 2025 on February 24, 2026. Following the release, the company will host a conference call and webcast for investors. Axogen is recognized for its innovative surgical solutions aimed at restoring peripheral nerve function.
Read more →AXGNAxogen Announces Proposed Public Offering of Common Stock
Axogen, Inc. has announced a proposed public offering of $85 million in common stock, with an additional option for underwriters to purchase up to $12.75 million more. The funds will be used for debt repayment, working capital, and general corporate purposes. The offering is subject to market conditions and regulatory approval.
Read more →AXGNAxogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Axogen, Inc. has announced the pricing of an upsized public offering of 4 million shares at $31.00 each, aiming to raise approximately $124 million. The offering is set to close on January 23, 2026, and proceeds will be utilized for debt repayment and general corporate purposes. The offering is managed by Wells Fargo Securities and Mizuho, among others.
Read more →AXGN▼ -5.8%on this news
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 ALACHUA and TAMPA, FL
Axogen, Inc. has announced preliminary unaudited revenue figures for the fourth quarter and full year of 2025. The company expects Q4 revenue to reach approximately $59.9 million, representing a 21.3% increase over the same quarter in 2024. Full-year revenue is projected to be around $225.2 million, marking a 20.2% increase over 2024 figures. The FDA's approval of the Avance product is a significant milestone that bolsters Axogen's market strategy and operational execution.
Read more →AXGN▲ +7%on this news
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
Axogen, Inc. will participate in the J.P. Morgan 2026 Healthcare Conference, scheduled for January 15, 2026. The company's management will present at 10:30 AM PST, and a live audio webcast will be available. Axogen focuses on innovative surgical solutions for peripheral nerve repair and has a diverse product portfolio.
Read more →AXGNAxogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) ALACHUA, FL and TAMPA, FL
Axogen, Inc. announced FDA approval of its Biologics License Application for AVANCE, an acellular nerve allograft intended for treating peripheral nerve discontinuities in patients aged 1 month or older. The approval comes under the Accelerated Approval pathway, based on evidence suggesting likely clinical benefits. The transition to a biologic classification is seen as a pivotal moment for Axogen, expected to enhance regulatory standing and market acceptance. However, further confirmatory trials are required to maintain this approval, raising potential risks.
Read more →About Axogen, Inc.
Headquarters13631 PROGRESS BLVD., ALACHUA, FL, 32615
Founded1977
BIOPHARMAWATCH ELITE PLUS
Trade the next AXGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime